C(N(CC)CC)C.[Cl:8][C:9]1[CH:14]=[CH:13][C:12]([CH:15]([N:19]2[CH2:24][CH2:23][CH:22]([C:25](=[O:33])[NH:26][CH:27]3[CH2:32][CH2:31][CH2:30][CH2:29][CH2:28]3)[CH2:21][CH2:20]2)[C:16](O)=[O:17])=[CH:11][CH:10]=1.[F:34][C:35]([F:51])([F:50])[C:36]1[CH:37]=[C:38]([S:46]([NH2:49])(=[O:48])=[O:47])[CH:39]=[C:40]([C:42]([F:45])([F:44])[F:43])[CH:41]=1.O>CN(C1C=CN=CC=1)C.CN(C=O)C>[CH:27]1([NH:26][C:25]([CH:22]2[CH2:21][CH2:20][N:19]([CH:15]([C:12]3[CH:11]=[CH:10][C:9]([Cl:8])=[CH:14][CH:13]=3)[C:16]([NH:49][S:46]([C:38]3[CH:37]=[C:36]([C:35]([F:51])([F:50])[F:34])[CH:41]=[C:40]([C:42]([F:43])([F:44])[F:45])[CH:39]=3)(=[O:47])=[O:48])=[O:17])[CH2:24][CH2:23]2)=[O:33])[CH2:32][CH2:31][CH2:30][CH2:29][CH2:28]1140 mg of triethylamine and 0.32 ml of 50% propylphosphonic acid anhydride (solution in DMF) are added to a solution of 150 mg of (4-chlorophenyl)-(4-cyclohexylcarbamoyl-piperidin1-yl)-acetic acid, 174 mg of 3,5-bis(trifluoromethyl)-benzenesulfonamide and 24 mg of DMAP in 6 ml of anhydrous DMF at 10°. The mixture obtained is stirred for ca. 60 hours at RT, solvent is evaporated off and the evaporation residue obtained is treated with EtAc and H2O. Two phases obtained are separated and the organic layer obtained is washed, dried and solvent is evaporated. The evaporation residue obtained is subjected to chromatography on silica gel. 1-[2-(3,5-Bis-trifluoromethyl-benzenesulfonylamino)-2-oxo-(4-chloro-phenyl)-ethyl]-piperidine-4-carboxylic acid cyclohexylamide is obtained.
読み込み中…